Local control and postponement of systemic therapy after modest dose radiotherapy in oligometastatic myxoid liposarcomas

Jules Lansu; Winan J. van Houdt; Kirsten van Langevelde; Piet L. A. van den Ende; Winette T. A. van der Graaf; Yvonne Schrage; Hester van Boven; Astrid N. Scholten; Rick L. Haas

doi:10.1016/j.radonc.2021.02.013

Local control and postponement of systemic therapy after modest dose radiotherapy in oligometastatic myxoid liposarcomas

Jules Lansu, Winan J. van Houdt, Kirsten van Langevelde, Piet L. A. van den Ende, Winette T. A. van der Graaf, Yvonne Schrage, Hester van Boven, Astrid N. Scholten, Rick L. Haas^*

^*Corresponding author for this work

GROW - Innovative Cancer Diagnostics & Therapy

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Introduction: Oligometastatic disease and/or oligoprogression in myxoid liposarcoma(oMLS) triggers discussions on local treatment options and delay of systemic treatments. We hypothesized that satisfactory local control and postponement of systemic therapy could be achieved with a modest radiotherapy(RT) dose in oMLS.

Methods: The DOREMY trial is a multicenter, phase 2 trial evaluating efficacy and toxicity of a modest RT dose in both localized and oMLS; this report presents the data of the oMLS cohort treated with 36 Gy in 12-18 fractions with optional subsequent metastasectomy. The primary endpoint was local progression free survival(LPFS). Secondary endpoints included postponement of systemic therapy, symptom reduction, radiological objective response, and toxicity.

Results: Nine patients with a total of 25 lesions were included, with a median follow-up of 23 months. The median number of lesions per patient was three and the trunk wall and bone were the most frequently affected sites. In lesions treated with definitive RT(n = 21), LPFS rates at 1, 2, and 3 years were respectively 73%, 61%, and 40%. Radiological objective response and clinical symptom reduction were achieved in 8/15(53%) and 9/10(90%) of the evaluable lesions, respectively. No local recurrences occurred in lesions treated with RT and metastasectomy(n = 4). For the entire study population, the median postponement of systemic therapy was 10 months. Grade >= 2 toxicity was observed in 2/9(22%) of patients.

Conclusions: This trial suggests that 36 Gy could possibly be effective to achieve local control, postpone systemic therapy and reduce symptoms in oMLS. Given the minimal toxicity this treatment could be reasonably considered in oMLS.

Original language	English
Pages (from-to)	33-39
Number of pages	7
Journal	Radiotherapy and Oncology
Volume	158
DOIs	https://doi.org/10.1016/j.radonc.2021.02.013
Publication status	Published - May 2021

Keywords

Myxoid liposarcoma
Myxoid liposarcomas
Soft tissue sarcoma
soft tissue sarcomas
Metastatic
Palliative therapy
Adjuvant radiotherapy
SOFT-TISSUE SARCOMA
TUMOR RESPONSE ASSESSMENT
RADIATION-THERAPY
PREOPERATIVE RADIOTHERAPY
PATHOLOGICAL RESPONSE
CHOI CRITERIA
TRABECTEDIN
CHEMOTHERAPY
DOXORUBICIN
METASTASES

Access to Document

10.1016/j.radonc.2021.02.013

1 Erratum / corrigendum / retractions

Corrigendum to "Local control and postponement of systemic therapy after modest dose radiotherapy in oligometastatic myxoid liposarcomas" [Radiother. Oncol. 158 (2021) 33-39]
Lansu, J., van Houdt, W. J., van Langevelde, K., van den Ende, P. L. A., van der Graaf, W. T. A., Schrage, Y., van Boven, H., Scholten, A. N. & Haas, R. L., Oct 2021, In: Radiotherapy and Oncology. 163, p. 245-245 1 p.
Research output: Contribution to journal › Erratum / corrigendum / retractions › Academic

Open Access

Cite this

Lansu, J., van Houdt, W. J., van Langevelde, K., van den Ende, P. L. A., van der Graaf, W. T. A., Schrage, Y., van Boven, H., Scholten, A. N., & Haas, R. L. (2021). Local control and postponement of systemic therapy after modest dose radiotherapy in oligometastatic myxoid liposarcomas. Radiotherapy and Oncology, 158, 33-39. https://doi.org/10.1016/j.radonc.2021.02.013

@article{d85efcd6ffe84d979fbae47e844c81b3,

title = "Local control and postponement of systemic therapy after modest dose radiotherapy in oligometastatic myxoid liposarcomas",

abstract = "Introduction: Oligometastatic disease and/or oligoprogression in myxoid liposarcoma(oMLS) triggers discussions on local treatment options and delay of systemic treatments. We hypothesized that satisfactory local control and postponement of systemic therapy could be achieved with a modest radiotherapy(RT) dose in oMLS.Methods: The DOREMY trial is a multicenter, phase 2 trial evaluating efficacy and toxicity of a modest RT dose in both localized and oMLS; this report presents the data of the oMLS cohort treated with 36 Gy in 12-18 fractions with optional subsequent metastasectomy. The primary endpoint was local progression free survival(LPFS). Secondary endpoints included postponement of systemic therapy, symptom reduction, radiological objective response, and toxicity.Results: Nine patients with a total of 25 lesions were included, with a median follow-up of 23 months. The median number of lesions per patient was three and the trunk wall and bone were the most frequently affected sites. In lesions treated with definitive RT(n = 21), LPFS rates at 1, 2, and 3 years were respectively 73%, 61%, and 40%. Radiological objective response and clinical symptom reduction were achieved in 8/15(53%) and 9/10(90%) of the evaluable lesions, respectively. No local recurrences occurred in lesions treated with RT and metastasectomy(n = 4). For the entire study population, the median postponement of systemic therapy was 10 months. Grade >= 2 toxicity was observed in 2/9(22%) of patients.Conclusions: This trial suggests that 36 Gy could possibly be effective to achieve local control, postpone systemic therapy and reduce symptoms in oMLS. Given the minimal toxicity this treatment could be reasonably considered in oMLS.(c) 2021 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 158 (2021) 33-39",

keywords = "Myxoid liposarcoma, Myxoid liposarcomas, Soft tissue sarcoma, soft tissue sarcomas, Metastatic, Palliative therapy, Adjuvant radiotherapy, SOFT-TISSUE SARCOMA, TUMOR RESPONSE ASSESSMENT, RADIATION-THERAPY, PREOPERATIVE RADIOTHERAPY, PATHOLOGICAL RESPONSE, CHOI CRITERIA, TRABECTEDIN, CHEMOTHERAPY, DOXORUBICIN, METASTASES",

author = "Jules Lansu and {van Houdt}, {Winan J.} and {van Langevelde}, Kirsten and {van den Ende}, {Piet L. A.} and {van der Graaf}, {Winette T. A.} and Yvonne Schrage and {van Boven}, Hester and Scholten, {Astrid N.} and Haas, {Rick L.}",

year = "2021",

month = may,

doi = "10.1016/j.radonc.2021.02.013",

language = "English",

volume = "158",

pages = "33--39",

journal = "Radiotherapy and Oncology",

issn = "0167-8140",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Local control and postponement of systemic therapy after modest dose radiotherapy in oligometastatic myxoid liposarcomas

AU - Lansu, Jules

AU - van Houdt, Winan J.

AU - van Langevelde, Kirsten

AU - van den Ende, Piet L. A.

AU - van der Graaf, Winette T. A.

AU - Schrage, Yvonne

AU - van Boven, Hester

AU - Scholten, Astrid N.

AU - Haas, Rick L.

PY - 2021/5

Y1 - 2021/5

N2 - Introduction: Oligometastatic disease and/or oligoprogression in myxoid liposarcoma(oMLS) triggers discussions on local treatment options and delay of systemic treatments. We hypothesized that satisfactory local control and postponement of systemic therapy could be achieved with a modest radiotherapy(RT) dose in oMLS.Methods: The DOREMY trial is a multicenter, phase 2 trial evaluating efficacy and toxicity of a modest RT dose in both localized and oMLS; this report presents the data of the oMLS cohort treated with 36 Gy in 12-18 fractions with optional subsequent metastasectomy. The primary endpoint was local progression free survival(LPFS). Secondary endpoints included postponement of systemic therapy, symptom reduction, radiological objective response, and toxicity.Results: Nine patients with a total of 25 lesions were included, with a median follow-up of 23 months. The median number of lesions per patient was three and the trunk wall and bone were the most frequently affected sites. In lesions treated with definitive RT(n = 21), LPFS rates at 1, 2, and 3 years were respectively 73%, 61%, and 40%. Radiological objective response and clinical symptom reduction were achieved in 8/15(53%) and 9/10(90%) of the evaluable lesions, respectively. No local recurrences occurred in lesions treated with RT and metastasectomy(n = 4). For the entire study population, the median postponement of systemic therapy was 10 months. Grade >= 2 toxicity was observed in 2/9(22%) of patients.Conclusions: This trial suggests that 36 Gy could possibly be effective to achieve local control, postpone systemic therapy and reduce symptoms in oMLS. Given the minimal toxicity this treatment could be reasonably considered in oMLS.(c) 2021 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 158 (2021) 33-39

AB - Introduction: Oligometastatic disease and/or oligoprogression in myxoid liposarcoma(oMLS) triggers discussions on local treatment options and delay of systemic treatments. We hypothesized that satisfactory local control and postponement of systemic therapy could be achieved with a modest radiotherapy(RT) dose in oMLS.Methods: The DOREMY trial is a multicenter, phase 2 trial evaluating efficacy and toxicity of a modest RT dose in both localized and oMLS; this report presents the data of the oMLS cohort treated with 36 Gy in 12-18 fractions with optional subsequent metastasectomy. The primary endpoint was local progression free survival(LPFS). Secondary endpoints included postponement of systemic therapy, symptom reduction, radiological objective response, and toxicity.Results: Nine patients with a total of 25 lesions were included, with a median follow-up of 23 months. The median number of lesions per patient was three and the trunk wall and bone were the most frequently affected sites. In lesions treated with definitive RT(n = 21), LPFS rates at 1, 2, and 3 years were respectively 73%, 61%, and 40%. Radiological objective response and clinical symptom reduction were achieved in 8/15(53%) and 9/10(90%) of the evaluable lesions, respectively. No local recurrences occurred in lesions treated with RT and metastasectomy(n = 4). For the entire study population, the median postponement of systemic therapy was 10 months. Grade >= 2 toxicity was observed in 2/9(22%) of patients.Conclusions: This trial suggests that 36 Gy could possibly be effective to achieve local control, postpone systemic therapy and reduce symptoms in oMLS. Given the minimal toxicity this treatment could be reasonably considered in oMLS.(c) 2021 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 158 (2021) 33-39

KW - Myxoid liposarcoma

KW - Myxoid liposarcomas

KW - Soft tissue sarcoma

KW - soft tissue sarcomas

KW - Metastatic

KW - Palliative therapy

KW - Adjuvant radiotherapy

KW - SOFT-TISSUE SARCOMA

KW - TUMOR RESPONSE ASSESSMENT

KW - RADIATION-THERAPY

KW - PREOPERATIVE RADIOTHERAPY

KW - PATHOLOGICAL RESPONSE

KW - CHOI CRITERIA

KW - TRABECTEDIN

KW - CHEMOTHERAPY

KW - DOXORUBICIN

KW - METASTASES

U2 - 10.1016/j.radonc.2021.02.013

DO - 10.1016/j.radonc.2021.02.013

M3 - Article

C2 - 33610624

SN - 0167-8140

VL - 158

SP - 33

EP - 39

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

ER -

Local control and postponement of systemic therapy after modest dose radiotherapy in oligometastatic myxoid liposarcomas

Abstract

Keywords

Access to Document

Research output

Corrigendum to "Local control and postponement of systemic therapy after modest dose radiotherapy in oligometastatic myxoid liposarcomas" [Radiother. Oncol. 158 (2021) 33-39]

Cite this